INTELLIA THERAPEUTICS

15,21

27-ноября-24 16:45:00

15 мин. задержка

Акции

+0,48

+3,26%

Сегодняшний диапазон

14,64 - 15,46

ISIN

N/A

Источник

NASDAQ

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 сен 2024 10:45:32 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 сен 2024 10:37:45 Источник NetDania Notify
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 сен 2024 16:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

01 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

24 июл 2024 16:01:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces CFO Transition

26 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

25 июн 2024 15:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

17 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Names Brian Goff to its Board of Directors

14 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

02 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

02 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

29 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 апр 2024 09:47:12 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

25 апр 2024 09:45:07 Источник NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 апр 2024 09:45:17 Источник NetDania Notify

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.